Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo

Hye Jin Jung; Joong Sup Shim; Hyang Burm Lee; Chang Jin Kim; Takashi Kuwano; Mayumi Ono; Ho Jeong Kwon

doi:10.1016/j.bbrc.2006.12.026

Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo

Hye Jin Jung, Joong Sup Shim, Hyang Burm Lee, Chang Jin Kim, Takashi Kuwano, Mayumi Ono, Ho Jeong Kwon

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G₂/M phase, which is associated with the increased expression of p21^WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.

Original language	English
Pages (from-to)	376-380
Number of pages	5
Journal	Biochemical and Biophysical Research Communications
Volume	353
Issue number	2
DOIs	https://doi.org/10.1016/j.bbrc.2006.12.026
Publication status	Published - 2007 Feb 9

Bibliographical note

Funding Information:
This study was supported by grants from the National R&D Program for Cancer Control, Ministry of Health & Welfare and from the Brain Korea 21 Project, Republic of Korea. H.J.J. was the recipient of a fellowship from the Korea Research Foundation.

All Science Journal Classification (ASJC) codes

Biophysics
Biochemistry
Molecular Biology
Cell Biology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1016/j.bbrc.2006.12.026

Fingerprint Dive into the research topics of 'Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo'. Together they form a unique fingerprint.

Cite this

@article{924a12fcdb8b44008b43eb6fd412bf24,

title = "Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo",

abstract = "The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.",

author = "Jung, {Hye Jin} and Shim, {Joong Sup} and Lee, {Hyang Burm} and Kim, {Chang Jin} and Takashi Kuwano and Mayumi Ono and Kwon, {Ho Jeong}",

note = "Funding Information: This study was supported by grants from the National R&D Program for Cancer Control, Ministry of Health & Welfare and from the Brain Korea 21 Project, Republic of Korea. H.J.J. was the recipient of a fellowship from the Korea Research Foundation.",

year = "2007",

month = feb,

day = "9",

doi = "10.1016/j.bbrc.2006.12.026",

language = "English",

volume = "353",

pages = "376--380",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Academic Press Inc.",

number = "2",

}

Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo. / Jung, Hye Jin; Shim, Joong Sup; Lee, Hyang Burm; Kim, Chang Jin; Kuwano, Takashi; Ono, Mayumi; Kwon, Ho Jeong.

In: Biochemical and Biophysical Research Communications, Vol. 353, No. 2, 09.02.2007, p. 376-380.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo

AU - Jung, Hye Jin

AU - Shim, Joong Sup

AU - Lee, Hyang Burm

AU - Kim, Chang Jin

AU - Kuwano, Takashi

AU - Ono, Mayumi

AU - Kwon, Ho Jeong

N1 - Funding Information: This study was supported by grants from the National R&D Program for Cancer Control, Ministry of Health & Welfare and from the Brain Korea 21 Project, Republic of Korea. H.J.J. was the recipient of a fellowship from the Korea Research Foundation.

PY - 2007/2/9

Y1 - 2007/2/9

N2 - The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.

AB - The efficient inhibition of angiogenesis is considered as a promising strategy for the treatment of angiogenesis-related diseases including cancer. Herein, we report that embellistatin, a bicyclic ketone compound known as a microtubule polymerization inhibitor, exhibits anti-angiogenic activity. Embellistatin inhibited in vitro angiogenesis of bovine aortic endothelial cells (BAECs) such as bFGF-induced invasion and tube formation as well as bFGF-induced mouse corneal angiogenesis in vivo. Notably, embellistatin exhibited stronger inhibition activity for the growth of BAECs than that of normal and cancer cell lines. Cell cycle analysis revealed that the compound arrests cell cycle at G2/M phase, which is associated with the increased expression of p21WAF1 and p53 partly. These results demonstrate that embellistatin may serve the basis for the development of new anti-angiogenic agents.

UR - http://www.scopus.com/inward/record.url?scp=33845880644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845880644&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.12.026

DO - 10.1016/j.bbrc.2006.12.026

M3 - Article

C2 - 17184734

AN - SCOPUS:33845880644

VL - 353

SP - 376

EP - 380

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -

Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this